Moneycontrol PRO
Upcoming Event:Join us for New HorAIzon from Oct 6-7, 2pm and be a part of exciting conversations on tech & innovation

Buy Ipca Laboratories; target of Rs 2480: Motilal Oswal

Motilal Oswal is bullish on Ipca Laboratories recommended buy rating on the stock with a target price of Rs 2480 in its research report dated April 11, 2021.

April 12, 2021 / 01:18 PM IST
  • bselive
  • nselive
Todays L/H

Motilal Oswal's research report on Ipca Laboratories

While doctors have resumed their clinics, partly on account of having received their vaccinations, patient footfall is yet to return to normal levels. Particularly, patient footfall remains low in the case of Pediatrics. IPCA has witnessed sustained growth momentum in the Pain segment. It has posted market share gains, on account of the pandemic, in products wherein smaller companies have been unable to meet supply requirements. Moreover, higher prescriptions for established brands such as Zerodol have enhanced growth prospects for IPCA in this segment. IPCA has outperformed in the Anti- Neoplastics, Central Nervous System (CNS), Dermatology, and Urology segments as well. IPCA has been a small player in Anti-Infective therapy – growth prospects have been impacted even further due to COVID. IPCA is gradually reviving sales in this therapy via new launches and increased traction in existing products. Overall, we expect a 14.5% sales CAGR in DF to INR27b (37% of sales) over FY21–23.


We value IPCA on a 24x 12M forward earnings basis to arrive at Target Price of INR2,480. Reiterate Buy.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Apr 12, 2021 01:18 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark